PBT 2
Alternative Names: PBT-2Latest Information Update: 23 Dec 2020
At a glance
- Originator Prana Biotechnology
- Developer Alterity Therapeutics
- Class Antidementias; Dimethylamines; Hydroxyquinolines; Ionophores; Small molecules
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Phase II Alzheimer's disease; Huntington's disease
- Preclinical Sepsis